Can Open-Source insulin systems match commercial ones without meal announcements?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females ≥ 18 years old currently residing in Canada or the United States of America (USA) * Having a clinical diagnosis of T1D for at least one year (based on the investigator's judgment; C peptide level and antibody determinations are not needed.) * Having been on OS-AID therapy for at least 2 weeks and using a Dexcom G6 or G7 CGM. * If using an ultra-rapid acting insulin, be willing to switch to a rapid-acting insulin, as the former are not recommended in the C-AID systems used in the study (due to the risk of cannula or pod blockage). * Accepting that personal pump setting parameters will be collected by the research team. This access will be limited to the study period. Exclusion Criteria: * Using regular insulin (Novolin ge Toronto or Humulin R) or U200 or U500 concentrated insulin (e.g. Humalog U200, Entuzity U500) * Participant-reported clinically significant nephropathy (eGFR \< 25 ml/min/1.73m2, planned or on dialysis), neuropathy (e.g., known uncontrolled gastroparesis) or retinopathy (e.g., proliferative retinopathy with ongoing active treatment such as laser photocoagulation or planned surgery) as judged by the investigator * Recent (\<3 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery) * Anticipated therapeutic change (including change of CGM sensor \[other than Dexcom sensors\] or AID system type, new antidiabetic drug initiation) between admission and end of the study * % of time spent out of automated mode exceeding 10% in last month's trial start * Anticipated need to use hydroxyurea during the study period (as it can interfere with CGM readings) * Pregnancy (ongoing or current attempt to become pregnant) * Breastfeeding * Plan to go abroad in a foreign country during the study period * Severe hypoglycemic episode within one month of screening * Severe hyperglycemic episode (including DKA) requiring hospitalization in the last 3 months * Current use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®) * Current use of SGLT-2 inhibitors or GLP1 agonists or other antidiabetic agents (Metformin, DPP-4 inhibitors) unless at a stable dose for at least 3 months, without anticipated change during the study and appropriate ketone testing is performed (for iSGLT2 treatment). * Known or suspected allergies to study products (e.g., Dexcom adhesive) * Other serious medical illnesses likely to interfere with study participation or with the ability to complete the study by the judgment of the investigator * Anticipation of a significant change in exercise or diet regimen between admission and end of the study (i.e., starting or stopping an organized sport; planned significant diet change) * Anticipated radiologic examination at the time of study assessment incompatible with CGM wear (e.g., MRI) * In the opinion of the investigator, a participant who is unable or unwilling to observe the contraindications of the study device.